In fact, AR-R17779 shows low cross-reactivity with 5-HT3 receptors, a common feature of other α7nAChR agonists, which might explain the absence of an anti-stroke effect for AR-R17779. This evidence concerns the gene CHRNA7 and stroke disorder.